Abstract
Aim The aim of this study was to evaluate the efficacy of intravitreal injection of ranibizumab for patients with chronic central serous chorioretinopathy (CCSC). Materials and methods A prospective interventional noncomparative study was conducted on nine patients with CCSC who were treated with an intravitreal injection of ranibizumab once. Visual acuity with Snellen's chart and the foveal thickness were studied before and after the injection. Results The mean age of the patients was 44.3 ± 5.7 years. After 1 month of intravitreal injection, visual acuity improved from 20/120 to 20/30 ( P P Conclusion Intravitreal injection of ranibizumab can be an optional treatment in patients with CCSC as it leads to an anatomic and functional improvement.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
